Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome
Orrin Devinsky, Anup D. Patel, Elizabeth A. Thiele, et al.
Neurology (2018) Vol. 90, Iss. 14
Open Access | Times Cited: 391

Showing 1-25 of 391 citing articles:

Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome
Orrin Devinsky, Anup D. Patel, J. Helen Cross, et al.
New England Journal of Medicine (2018) Vol. 378, Iss. 20, pp. 1888-1897
Open Access | Times Cited: 826
Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial
Elizabeth A. Thiele, Eric D. Marsh, Jacqueline A. French, et al.
The Lancet (2018) Vol. 391, Iss. 10125, pp. 1085-1096
Closed Access | Times Cited: 763
A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans
Sophie Millar, Nicole L. Stone, Andrew Yates, et al.
Frontiers in Pharmacology (2018) Vol. 9
Open Access | Times Cited: 425
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects
Lesley Taylor, Barry E. Gidal, Graham Blakey, et al.
CNS Drugs (2018) Vol. 32, Iss. 11, pp. 1053-1067
Open Access | Times Cited: 370
Cannabidiol Adverse Effects and Toxicity
Marilyn A. Huestis, Renata Solimini, Simona Pichini, et al.
Current Neuropharmacology (2019) Vol. 17, Iss. 10, pp. 974-989
Open Access | Times Cited: 367
The Case for the Entourage Effect and Conventional Breeding of Clinical Cannabis: No “Strain,” No Gain
Ethan B. Russo
Frontiers in Plant Science (2019) Vol. 9
Open Access | Times Cited: 267
Immune Responses Regulated by Cannabidiol
James M. Nichols, Barbara L.F. Kaplan
Cannabis and Cannabinoid Research (2019) Vol. 5, Iss. 1, pp. 12-31
Open Access | Times Cited: 235
Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials
Edward Chesney, Dominic Oliver, Alastair Green, et al.
Neuropsychopharmacology (2020) Vol. 45, Iss. 11, pp. 1799-1806
Open Access | Times Cited: 221
Cannabidiol: pharmacology and therapeutic targets
Stevie C. Britch, Shanna Babalonis, Sharon Walsh
Psychopharmacology (2020) Vol. 238, Iss. 1, pp. 9-28
Open Access | Times Cited: 220
Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials
Serena Silvestro, Santa Mammana, Eugenio Cavalli, et al.
Molecules (2019) Vol. 24, Iss. 8, pp. 1459-1459
Open Access | Times Cited: 218
Cannabidiol for Pain Treatment: Focus on Pharmacology and Mechanism of Action
Jakub Mlost, Marta Bryk, Katarzyna Starowicz
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 22, pp. 8870-8870
Open Access | Times Cited: 215
Medicinal use of cannabis based products and cannabinoids
Tom P. Freeman, Chandni Hindocha, Sebastian F Green, et al.
BMJ (2019), pp. l1141-l1141
Open Access | Times Cited: 202
Clinicians’ Guide to Cannabidiol and Hemp Oils
Harrison VanDolah, Brent A. Bauer, Karen F. Mauck
Mayo Clinic Proceedings (2019) Vol. 94, Iss. 9, pp. 1840-1851
Open Access | Times Cited: 200
Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis
Simona Lattanzi, Francesco Brigo, Eugen Trinka, et al.
Drugs (2018) Vol. 78, Iss. 17, pp. 1791-1804
Open Access | Times Cited: 198
Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex
Elizabeth A. Thiele, E. Martina Bebin, Hari Bhathal, et al.
JAMA Neurology (2020) Vol. 78, Iss. 3, pp. 285-285
Open Access | Times Cited: 195
The Pharmacoresistant Epilepsy: An Overview on Existent and New Emerging Therapies
Antonella Fattorusso, Sara Matricardi, Elisabetta Mencaroni, et al.
Frontiers in Neurology (2021) Vol. 12
Open Access | Times Cited: 187
Long‐term safety and treatment effects of cannabidiol in children and adults with treatment‐resistant epilepsies: Expanded access program results
Jerzy P. Szaflarski, E. Martina Bebin, Anne M. Comi, et al.
Epilepsia (2018) Vol. 59, Iss. 8, pp. 1540-1548
Open Access | Times Cited: 185
Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders
Daniel Friedman, Jacqueline A. French, Mauro Maccarrone
The Lancet Neurology (2019) Vol. 18, Iss. 5, pp. 504-512
Closed Access | Times Cited: 185
A Phase 1, Open‐Label, Pharmacokinetic Trial to Investigate Possible Drug‐Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects
Gilmour Morrison, Julie C. Crockett, Graham Blakey, et al.
Clinical Pharmacology in Drug Development (2019) Vol. 8, Iss. 8, pp. 1009-1031
Open Access | Times Cited: 175
Towards Better Delivery of Cannabidiol (CBD)
Sophie Millar, Ryan Maguire, Andrew Yates, et al.
Pharmaceuticals (2020) Vol. 13, Iss. 9, pp. 219-219
Open Access | Times Cited: 172
Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes
Orrin Devinsky, Chloe Verducci, Elizabeth A. Thiele, et al.
Epilepsy & Behavior (2018) Vol. 86, pp. 131-137
Closed Access | Times Cited: 162
Cannabis and Its Secondary Metabolites: Their Use as Therapeutic Drugs, Toxicological Aspects, and Analytical Determination
Joana Gonçalves, Tiago Rosado, Sofia Soares, et al.
Medicines (2019) Vol. 6, Iss. 1, pp. 31-31
Open Access | Times Cited: 159
Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy
Valentina Franco, Emilio Perucca
Drugs (2019) Vol. 79, Iss. 13, pp. 1435-1454
Closed Access | Times Cited: 147
Reasons for cannabidiol use: a cross-sectional study of CBD users, focusing on self-perceived stress, anxiety, and sleep problems
Julie Moltke, Chandni Hindocha
Journal of Cannabis Research (2021) Vol. 3, Iss. 1
Open Access | Times Cited: 109
Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications
Ainhoa Bilbao, Rainer Spanagel
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 107
Page 1 - Next Page

Scroll to top